Who Paid My Doc
Matthew Weissler
Hematology & Oncology White Plains, NY Medical Doctor
NPI 1528225695 CMS profile 341114
210 Westchester Ave, White Plains, NY 10604
General payments
$12
Research payments
$0
Ownership & investment interest
$0
Through program year 2021, Matthew Weissler of White Plains, NY is reported in the CMS Open Payments database as having received $12 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 1st percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $12 | 1 |
Beside peers
- Matthew Weissler
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Matthew Weissler were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Matthew Weissler | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $529 | $121–$2,516 | $163 |
| 2020 | $0 | $339 | $82–$2,213 | $114 |
| 2021 | $12 | $263 | $49–$1,965 | $132 |
| 2022 | $0 | $416 | $103–$2,395 | $149 |
| 2023 | $0 | $542 | $125–$2,646 | $160 |
| 2024 | $0 | $692 | $141–$3,008 | $164 |
| 2025 | $0 | $683 | $143–$3,154 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 42 drugsPart D claims
1,728
Drug cost
$5,923,229
Branded share of claims
33.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Pomalyst Pomalidomide | Brand | 39 | $879,368 | |
| Brukinsa Zanubrutinib | Brand | 51 | $748,490 | |
| Imbruvica Ibrutinib | Brand | 36 | $558,032 | |
| Revlimid Lenalidomide | Brand | 25 | $471,071 | |
| Verzenio Abemaciclib | Brand | 29 | $455,692 | |
| Cabometyx Cabozantinib S-Malate | Brand | 16 | $433,692 | |
| Lenalidomide | Generic | 27 | $371,870 | |
| Orserdu Elacestrant Hcl | Brand | 15 | $331,060 | |
| Gammaked Immune Globul G/Gly/Iga Avg 46 | Brand | 11 | $322,203 | |
| Tabrecta Capmatinib Hydrochloride | Brand | 14 | $313,210 |
The 10 drugs with the highest cost, of 42 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 171 billing codesPaid by Medicare
$4,367,607
Medicare patients
628
Services billed
340,618
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 43% | |
| Cancer | 40% | |
| Chronic kidney disease | 36% | |
| Diabetes | 31% | |
| Ischemic heart disease | 29% | |
| Atrial fibrillation | 21% | |
| COPD | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 11 | 21,800 | $977,259 |
| Injection, denosumab, 1 mg J0897 | Office | 24 | 8,340 | $173,634 |
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg Q5107 | Office | 12 | 5,669 | $117,457 |
| Injection, ferric carboxymaltose, 1 mg J1439 | Office | 57 | 86,250 | $75,107 |
| Injection, epoetin alfa, biosimilar, (retacrit) (for non-esrd use), 1000 units Q5106 | Office | 16 | 3,460 | $19,625 |
| Injection, leucovorin calcium, per 50 mg J0640 | Office | 15 | 2,484 | $8,853 |
| Injection, fluorouracil, 500 mg J9190 | Office | 18 | 1,681 | $3,890 |
| Injection, fosaprepitant, 1 mg J1453 | Office | 20 | 13,650 | $1,527 |
| Injection, iron sucrose, 1 mg J1756 | Office | 21 | 8,800 | $1,393 |
| Injection, oxaliplatin, 0.5 mg J9263 | Office | 12 | 20,600 | $1,145 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in New York
Michael Schuster
Hematology & Oncology · New York, NY
Charles Sawyers
Hematology & Oncology · New York, NY
Manuel Hidalgo-Medina
Hematology & Oncology · New York, NY
Francis Arena
Hematology & Oncology · Lake Success, NY
Sanjeev Jain
Hematology & Oncology · East Patchogue, NY
Ross Levine
Hematology & Oncology · New York, NY
Related records
Hematology & Oncology in New York
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.